脓毒性休克非存活者补充左卡尼汀后酰基肉碱持续升高
该研究检测了参加随机对照试验的脓毒性休克患者血清样本,左卡尼汀组16例、安慰剂组15例,在入组时(T0)、输注完成后12小时(T24)及入组后48小时(T48)测定酰基肉碱、游离脂肪酸和胰岛素。1年死亡率左卡尼汀组为8/16(50%),安慰剂组为12/15(80%)。入组时非存活者的游离肉碱、C2、C3和C8酰基肉碱较高;左卡尼汀治疗使所有测定的酰基肉碱升高,效应在输注完成后持续至少36小时,且在非存活者中更明显。葡萄糖、乳酸和胰岛素水平未因生存状态或治疗分组而不同。
要点
- 脓毒性休克患者1年死亡率:左卡尼汀组8/16(50%),安慰剂组12/15(80%)。
- 入组时非存活者的游离肉碱、C2、C3和C8酰基肉碱高于存活者。
- 左卡尼汀治疗使所有测定的酰基肉碱升高,效应在输注完成后持续至少36小时。
- 左卡尼汀引起的酰基肉碱升高在非存活者中更明显。
- 葡萄糖、乳酸和胰岛素水平未因生存状态或治疗分组而不同。
适用人群与场景
- 参加随机对照试验的脓毒性休克患者,左卡尼汀组16例、安慰剂组15例。
处置流程与药物剂量
- 左卡尼汀组给予左卡尼汀,安慰剂组给予安慰剂;在入组时(T0)、输注完成后12小时(T24)及入组后48小时(T48)采集血清样本检测酰基肉碱、游离脂肪酸和胰岛素。
研究设计与关键结果
- 研究类型:随机对照试验的二次分析;样本量31例(左卡尼汀组16例、安慰剂组15例);人群为脓毒性休克患者。
- 1年死亡率:左卡尼汀组8/16(50%),安慰剂组12/15(80%)。
- 入组时非存活者的游离肉碱、C2、C3和C8酰基肉碱高于存活者。
- 左卡尼汀治疗使所有测定的酰基肉碱升高,效应在输注完成后持续至少36小时,且在非存活者中更明显。
- 部分游离脂肪酸呈现相似但不太一致的模式。
- 葡萄糖、乳酸和胰岛素水平未因生存状态或治疗分组而不同。
证据类型、等级与局限
- 证据类型:随机对照试验的二次分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,非存活者对左卡尼汀表现出与存活者不同的代谢反应,可能提示存在预先存在或更严重的代谢紊乱,限制了任何治疗获益反应。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Sepsis-induced metabolic disturbances include hyperlactatemia, disruption of glycolysis, protein catabolism, and altered fatty acid metabolism. It may also lower serum L-carnitine that supports the use of L-carnitine supplementation as a treatment to ameliorate several of these metabolic consequences.
METHODS: To further understand the association between L-carnitine-induced changes in serum acylcarnitines, fatty acid metabolism and survival, serum samples from (T0), 12 hfollowing completion (T24) of L-carnitine (n = 16) or placebo (n = 15) administration, and 48 h (T48) after enrollment from patients with septic shock enrolled in a randomized control trial were assayed for acylcarnitines, free fatty acids, and insulin. Data were analyzed comparing 1-year survivors and nonsurvivors within treatment groups.
RESULTS: Mortality was 8 of 16 (50%) and 12 of 15 (80%) at 1 year for L-carnitine and placebo-treated patients, respectively. Free carnitine, C2, C3, and C8 acylcarnitines were higher among nonsurvivors at enrollment. L-Carnitine treatment increased levels of all measured acylcarnitines; an effect that was sustained for at least 36 h following completion of the infusion and was more prominent among nonsurvivors. Several fatty acids followed a similar, though less consistent pattern. Glucose, lactate, and insulin levels did not differ based on survival or treatment arm.
CONCLUSIONS: In human patients with septic shock, L-Carnitine supplementation increases a broad range of acylcarnitine concentrations that persist after cessation of infusion, demonstrating both immediate and sustained effects on the serum metabolome. Nonsurvivors demonstrate a distinct metabolic response to L-carnitine compared with survivors, which may indicate preexisting or more profound metabolic derangement that constrains any beneficial response to treatment.
参考来源
- Puskarich MA, Evans CR, Karnovsky A, et al. Septic Shock Nonsurvivors Have Persistently Elevated Acylcarnitines Following Carnitine Supplementation. Shock. 2018. PMID: 29384504. doi:10.1097/SHK.0000000000000997
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。